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ABSTRACT
Background and objectives: Rheumatoid arthritis (RA)
causes considerable disability and often results in loss of
work capacity and productivity. This study evaluated the
impact of adalimumab, a tumour necrosis factor
antagonist with demonstrated efficacy in RA, on long-
term employment.
Methods: Data from an open-label extension study
(DE033) of 486 RA patients receiving adalimumab
monotherapy who previously did not respond to at least
one disease-modifying antirheumatic drug (DMARD) and
had baseline work status information were compared with
data from 747 RA patients receiving DMARD treatment in
a Norway-based longitudinal registry. Primary outcomes
included the time patients continued working at least part
time and the likelihood of stopping work. Secondary
outcomes included American College of Rheumatology
(ACR) and European League Against Rheumatism
(EULAR) responses and disease remission. Outcomes
were compared 6, 12 and 24 months after enrolment.
Results: During a 24-month period, the 158 patients who
received adalimumab and were working at baseline
worked 7.32 months longer (95% CI 4.8 to 9.1) than did
the 180 patients treated with DMARDs, controlling for
differences in baseline characteristics. Regardless of
baseline work status, patients receiving adalimumab
worked 2.0 months longer (95% CI 1.3 to 2.6) and were
significantly less likely to stop working than those
receiving DMARDs (HR 0.36 (95% CI 20.30 to 0.42) for
all patients and 0.36 (95% CI 0.15 to 0.85) for patients
working at baseline, respectively). The patients who
received adalimumab were also considerably more likely
to achieve ACR responses and disease remission than
DMARD-treated patients. Patients who achieved EULAR
good response and remission were less likely to stop
working, but this relationship was only seen in patients
receiving DMARDs.
Conclusions: Patients with RA who received adalimu-
mab experienced considerably longer periods of work and
continuous employment, and greater rates of clinical
responses, than patients receiving DMARDs. The
mechanism by which adalimumab decreases likelihood of
stopping work seems to be different from that of DMARD
treatment and independent of clinical responses.
Rheumatoid arthritis (RA), a chronic inflammatory
disease of unknown aetiology affecting 0.5% to
1.0% of the adult population,
1–3 has a negative
impact on the physical, psychological and social
health of patients
4 and may cause considerable
disability.
5–9 The inability to perform activities of
daily living, impairment in quality of life and loss
of work capacity eventually lead to increased direct
and, to a larger extent, indirect costs.
10–16 Indirect
costs are consistently greater than direct costs and
can be attributed to reduced functionality and
attendance at work for those patients still
employed,
17–20 early retirement due to RA and sick
leave by employed patients.
21 In one study, the
largest components of annual workplace cost
attributable to arthritis were decreased productiv-
ity (41%) and wages lost from stopping work or
changing jobs (37%).
22
There is no cure for RA, and treatments have
been aimed at providing symptomatic relief,
slowing joint damage and preventing functional
disability. Although aggressive management with
standard therapies has provided symptomatic relief
for many patients, tumour necrosis factor (TNF)
antagonists have further improved the manage-
ment of RA
23 24 through marked reductions in the
manifestations of RA, improvements in function,
slowed radiographic progression and improve-
ments in patients’ quality of life.
25–28 However,
data on whether these treatments affect work-
related productivity are limited.
29 Data are also
needed to determine whether response to treat-
ment with TNF antagonists has consequences for
work capacity.
A cross-sectional analysis of randomised con-
trolled trials of etanercept showed greater employ-
ment rates among patients treated with this TNF
antagonist.
30 However, longitudinal studies can
examine the effects of illness over time and may
provide a more robust picture of the impacts of
comparative therapies than can cross-sectional
studies. The objective of this study was to evaluate
the long-term impact of therapy with the TNF
antagonist adalimumab on employment among
patients with RA. Data from RA patients who
participated in a recent European open-label
extension study of adalimumab were compared
with data from patients enrolled in a Norwegian
longitudinal observational study involving treat-
ment with conventional disease-modifying anti-
rheumatic drugs (DMARDs).
METHODS
Study populations
We obtained the data for these analyses from two
sources. Information on patients receiving adali-
mumab therapy was obtained from an open-label
extension study conducted by Abbott Laboratories
(study DE033). The extension study enrolled
patients who had completed one of six adalimu-
mab clinical trials.
31 These trials involved patients
from Europe, Australia and Canada who had not
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Patients entering the extension study may have received
placebo, low-dose adalimumab or standard-dose adalimumab
in the previous clinical trial. All patients participating in DE033
received adalimumab 40 mg every other week. All of the
previous six adalimumab clinical trials leading to DE033 had
similar inclusion criteria. In general, patients enrolled had:
c moderate to severe RA for a mean of approximately 12
years;
c on average, been treated with approximately four DMARDs
previously;
c a mean 28-joint Disease Activity Score (DAS28) of
approximately 5.2.
Dropout rates from the six prior adalimumab clinical studies
were examined to ensure that a large number of non-responders
had not dropped out before entry into this open-label study.
Study discontinuations resulting from adverse events occurred
in 3% (22/816) of patients and those owing to lack of efficacy
occurred in 11% (90/816) of patients initially receiving
adalimumab in the preceding studies.
32–37
No control or comparison group was included in the DE033
open-label extension study. To evaluate longitudinal differences
among patients receiving adalimumab in the current study, we
compared the DE033 population with patients from the
Norway-based longitudinal registry (NOR-DMARD) of patients
with RA and other inflammatory arthropathies being treated
with DMARDs.
38 Patients with RA who were prescribed
methotrexate or leflunomide (alone or in combination with
other DMARDs) after previously not responding to least one
DMARD regimen (consistent with the inclusion criteria for
DE033) were eligible for this study. Other inclusion criteria for
DE033 and NOR-DMARD patients were comparable. Data
from each group of patients were included for up to 2 years
following study enrolment. However, patients in the NOR-
DMARD study with less than 2 years of follow-up data (owing
to either study discontinuation or study enrolment less than 2
years prior to this analysis) were also included in analyses for
time points prior to 2 years (baseline, 6 months and
12 months).
Outcome measures
The primary outcome measures for this study were the time
patients remained at work and the likelihood of stopping work.
For these outcome measures, individuals who were working at
least part time at baseline (ie, DE033 or NOR-DMARD
enrolment) were assessed at 6, 12 and 24 months to determine
whether they were still working at least part time. Owing to
small numbers, no differentiation was made between those
working full time and those working part time. As these data
were collected only at 6, 12 and 24 months, analyses used the
midpoint of each interval for duration of time worked. The
same assumption was applied to patients from the DE033 study
and the NOR-DMARD registry.
We also included three secondary outcome measures in this
study:
c the likelihood of achieving American College of
Rheumatology (ACR) responses (ACR20, ACR50 and
ACR70) at 6, 12 and 24 months following enrolment in
DE033 or NOR-DMARD;
c the likelihood of experiencing a good response according to
the European League Against Rheumatism (EULAR) criteria;
c the likelihood of experiencing disease remission as measured
by the DAS28.
Calculations of ACR outcome measures have been described
elsewhere.
39 For this analysis, numbers of swollen and tender
joints were based on counts of 28 joints, as only 28-joint counts
were available in the NOR-DMARD data set. Patient-rated
assessment of pain and physician-rated assessments of global
disease activity were evaluated using 100-point visual analogue
scales.
The DAS28 was calculated (based on erythrocyte sedimenta-
tion rate) at each available time point (baseline and 6, 12 and
24 months).
40 A EULAR response was calculated based on a
DAS28 score (3.2 and a decrease in DAS28 from baseline
.1.2.
41 Consistent with previous analyses, a DAS28 ,2.6 was
used to identify patients in disease remission.
Analyses
We compared baseline clinical, demographic and working
characteristics for DE033 and NOR-DMARD patients using x
2
tests (for dichotomous variables) and Student t tests (for
continuous variables). Baseline characteristics with statistically
significant differences were then controlled for in subsequent
multivariate regressions. The patients’ average monthly wage
was used to calculate work loss, so the financial implication was
from a patient perspective rather than an employer perspective.
For the analysis of available work data, we assumed that
patients who stopped working did not return to work at a later
time point. Therefore, for the analysis of the likelihood of
stopping work at 6, 12 and 24 months, patients who had
previously stopped working before one of these time points
were included in all subsequent analyses, even if they had
missing work data or incomplete study follow-up. Patients who
were working at one time point and did not have work data for
subsequent time points were excluded from subsequent
analyses.
We used multivariate ordinary least square regression to
compare duration worked (ie, time patients remained at work)
for patients receiving adalimumab versus DMARDs, controlling
for significant differences in baseline characteristics. Separate
regression analyses were performed for the entire study
population (which included individuals who were not working
at study entry) and the subset of the population working at
baseline. Collinearity diagnostics were performed for regression
of both the entire study population and the population working
at baseline. Substantial collinearity was present if the largest
condition index was greater than 100.
In addition, multivariate proportional hazards (PH) regression
was used to evaluate the likelihood of stopping work while
Figure 1 Percentage of study participants working atenrolment who have
continued working over time. NOR-DMARD, patients receiving disease-
modifying antirheumatic drugs from Norway-based longitudinal registry.
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baseline clinical differences. Two separate PH analyses were
performed: one involving all study patients, whether or not
they were working at baseline, and a second that included only
individuals who were working at baseline. For these analyses,
stopping work was an event; individuals who had been enrolled
in the study for less than 2 years and who were working at their
last study visit, as well as individuals who were still working at
2 years, were considered censored. Diagnostics run for both the
overall study population and the population working at baseline
indicated that the PH assumption was valid.
Multivariate PH regressions were also used to compare the
likelihood (hazard ratio) of achieving ACR outcomes (ACR20,
ACR50 or ACR70), a good EULAR response and disease
remission based on DAS28 scores over the period of available
follow-up data while controlling for the clinical factors that
differed between the groups at baseline. In this PH regression,
achievement of these clinical outcomes was an event, and the
time to the first such event was used in the analysis. Patients
who did not achieve a particular outcome within their follow-
up period were considered censored for that outcome.
We also performed multivariate PH regressions across
treatment groups to examine whether achievement of clinical
response influenced the likelihood of stopping work. All
analyses were conducted using SAS V.9.1. Confidence intervals
for the differences in the means are provided. No interpolation
of missing data was performed.
RESULTS
Most of the 505 patients in DE033 (69%) were from northern
Europe (Belgium, the Netherlands, Great Britain, France,
Germany, Austria and Switzerland). An additional 10% of
patients were from southern Europe (Spain and Italy), and the
remaining 21% were from Australia and Canada. Of the 505
patients enrolled in DE033, 68 had received placebo in the
preceding clinical studies; the remainder continued adalimumab
therapy in this open-label extension. Information on work
status at baseline (ie, study entry) was available for 486 DE033
patients and 747 NOR-DMARD patients, and only these
populations were included in the study analyses.
To appropriately compare outcomes between DE033 patients
and NOR-DMARD patients, we first compared baseline
characteristics for all patients and for the subset of patients
who were working at baseline, n=158 and n=180, respec-
tively; table 1). In the overall population, there were no
significant differences in the sex distribution or mean duration
of RA, but significant differences were observed in demographic
and several disease activity variables. The magnitude in the
difference for clinical measures (acute-phase reactants and joint
counts) was relatively small, whereas the differences in
responses to subjective assessments (visual analogue scale
measures) were proportionally larger. This difference may be a
reflection of DE033 being a continuation of clinical trials that
participating patients had already completed, whereas the
NOR-DMARD patients were just beginning a new study
experience. However, we included all of the statistically
significant baseline factors in the subsequent multivariate
regressions. When baseline characteristics were examined for
those patients working at baseline, age, disease duration, C-
reactive protein concentration and erythrocyte sedimentation
rate were lower for patients working at baseline than for the
entire cohort.
Figure 1 shows the percentage of study participants working
at enrolment who continued working over time. At 12 months,
179 patients were working (117 in the adalimumab group and
62 in the DMARD group), whereas 144 patients (108 and 36,
respectively) were working at 24 months. A significantly greater
percentage of patients in the adalimumab group than in the
DMARD group were working at 12 months (mean difference
13.8%; 95% CI 3.4% to 24.2%) and at 24 months (mean
difference 17.6%, 95% CI 4.6% to 30.7%) (p,0.05). Multivariate
linear regression analyses were performed to evaluate the
duration of work while controlling for baseline differences
between the two populations. Among all patients (those
working and those not working at enrolment), those receiving
adalimumab worked for 0.17 years (approximately 9 weeks)
longer than those receiving DMARDs over the study period of
Table 1 Baseline characteristics of DE033 and NOR-DMARD patients
Characteristic
All patients Patients working at baseline
Mean (95% CI)
95% CI*
Mean (95% CI)
95% CI* DE033 (n=486)
NOR-DMARD
(n=747) DE033 (n=158) NOR-DMARD (n=180)
Disease duration (years) 12.3 (11.6 to 13.0) 13.0 (12.3 to 13.6) 21.7 to 0.4 10.5 (9.4 to 11.6) 10.7 (9.5 to 11.9) 21.8 to 1.5
Women (%) 78.2 (74.5 to 81.9) 74.3 (71.2 to 77.4) 28.8 to 10.0 69.0 (61.7 to 76.3) 68.3 (61.5 to 75.2) 29.3 to 10.6
Working at baseline (%) 32.5 (28.3 to 36.7) 24.1 (21.0 to 27.2) 3.3 to 13.5 – – –
Age (years) 53.7 (52.6 to 54.8) 57.0 (56.1 to 58.0) 24.8 to 21.9 45.3 (43.7 to 46.9) 48.1 (46.7 to 49.5) 24.9 to 20.7
C-reactive protein (mg/L) 195 (172 to 218) 245 (226 to 263) 279 to 221 190 (150 to 229) 187 (157 to 228) 247 to 52
Erythrocyte sedimentation rate
(mm/h)
31.4 (29.4 to 33.5) 28.7 (27.1 to 30.4) 0.1 to 5.3 27.4 (24.1 to 30.7) 20.3 (17.7 to 23.0) 2.9 to 11.2
Swollen joint count (28 joints) 6.1 (5.6 to 6.6) 8.1 (7.7 to 8.5) 22.7 to 21.4 6.6 (5.6 to 7.5) 7.4 (6.6 to 8.2) 22.1 to 0.4
Tender joint count (28 joints) 7.0 (6.4 to 7.7) 8.2 (7.7 to 8.7) 22.0 to 20.4 7.0 (5.9 to 8.1) 7.0 (6.1 to 7.9) 21.4 to 1.4
DAS28 4.2 (4.0 to 4.3) 4.9 (4.8 to 5.0) 20.9 to 20.6 4.2 (3.9 to 4.4) 4.6 (4.4 to 4.8) 20.7 to 20.2
Patient-rated joint pain
(0–100 VAS)
33.0 (30.9 to 35.2) 50.9 (49.3 to 52.5) 220.5 to 215.3 31.4 (27.7 to 35.2) 44.9 (41.7 to 48.2) 218.4 to 28.6
Patient-rated global disease
activity (0–100 VAS)
27.3 (25.3 to 29.2) 42.5 (41.2 to 43.7) 217.4 to 213.0 32.2 (28.5 to 35.8) 49.4 (46.0 to 52.8) 222.2 to 212.2
Physician-rated global disease
activity (0–100 VAS)
33.3 (31.2 to 35.4) 54.9 (53.2 to 56.5) 224.2 to 218.9 26.8 (23.5 to 30.1) 39.8 (37.3 to 42.2) 217.0 to 29.0
*Confidence intervals refer to the difference between the DE033 and NOR-DMARD groups within the category ‘‘All patients’’ or ‘‘Patients working at baseline’’.
DAS28, 28-joint Disease Activity Score; NOR-DMARD, patients receiving disease-modifying antirheumatic drugs from Norway-based longitudinal registry; VAS, visual analogue
scale.
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at least part time at baseline (180 (24.1%) of the DMARD group
and 158 (32.5%) of the adalimumab group), patients receiving
adalimumab worked for 0.61 years (approximately 32 weeks)
longer than did the patients receiving DMARDs over the 2
study years (95% CI 0.42 to 0.79; table 2). We did not observe
substantial collinearity among the independent variables for
these regressions. Of the 1233 patients enrolled in the study, 895
patients were not working at baseline. Of these, 17 were
working at 6 months (7 adalimumab-treated and 10 DMARD-
treated patients), 19 were working at 12 months (8 adalimu-
mab-treated and 11 DMARD-treated patients) and 15 were
working at 24 months (6 adalimumab-treated and 9 DMARD-
treated patients). Therefore, an overwhelming majority (.95%)
of patients who stopped working did not return to work.
To further control for baseline differences between the two
study populations and available study enrolment over the 3-
year period, we performed multivariate PH regression. Patients
in the adalimumab group were significantly less likely to stop
working than patients in the DMARD group (table 2). Results
were consistent for both the overall study population and for
the subpopulation of patients who were working at study
enrolment. Among DE033 patients, we also evaluated whether
treatment allocation (adalimumab or placebo) in the six clinical
trials that preceded DE033 influenced the likelihood of stopping
work. Using the multivariate PH regression presented in table 2,
treatment arm allocation in the previous clinical trials was not
significantly associated with likelihood of stopping work (data
not shown).
Table 3 shows the results of PH regression analyses for the
secondary outcome variables. Patients treated with adalimumab
were significantly more likely to achieve ACR20, ACR50,
ACR70, a good EULAR response and DAS28 remission
(table 3) than were patients receiving DMARDs. Among the
DE033 patients, we also evaluated whether treatment allocation
(adalimumab or placebo) in the preceding clinical trials
influenced likelihood of achieving clinical responses. In contrast
to the results of the similar subanalysis performed to evaluate
stopping work, treatment allocation was significantly associated
with likelihood of achieving responses. Patients who received
placebo in clinical trials that preceded DE033, and thus received
adalimumab for the first time in DE033 (ie, they were
adalimumab-naı ¨ve when they entered DE033), were more likely
to achieve ACR20 (p=0.047), ACR50 (p=0.03) and ACR70
(p=0.006) responses than were patients who received adalimu-
mab before entering DE033 (data not shown). However, the
treatment arm (adalimumab or placebo) in clinical trials before
DE033 was not significantly associated with achieving a EULAR
good response or with experiencing disease remission (either
among all patients or among the subgroup of DE033 patients
without disease remission at study enrolment).
Table 4 presents multivariate PH regression analysis results
evaluating the relationship between the primary and secondary
study outcomes—ie, stopping work and achieving clinical
responses, for the entire study population (combining adalimu-
mab and DMARD groups). Patients who achieved ACR
outcomes at each of the three study time points were less
likely to stop working. This relationship was observed most
strongly for patients achieving the ACR20 and ACR50 out-
comes. Similar associations were also observed for good
response to EULAR criteria and DAS28 remission (table 4).
Table 4 also presents separate analyses evaluating the
relationship between stopping work and achieving clinical
responses for adalimumab and DMARD patients.
Substantially different results were observed for the two
populations. Among DMARD patients, a significant relation-
ship was observed between achieving a clinical response and
continuing to work. In contrast, among adalimumab patients,
the relationship between achieving a clinical response and
likelihood of continuing work was not statistically significant
for any of the clinical responses. This suggests that the
mechanism by which adalimumab leads to decreased rates of
stopping work is independent of the observed increased rates of
achieving clinical outcomes.
DISCUSSION
Our study has two main findings. First, patients with RA
receiving adalimumab were considerably more likely to con-
tinue working. Patients in this study who were receiving
adalimumab worked for a longer duration of the 2-year study
period than did patients receiving DMARDs (fig 1, table 2).
These patients also were more likely to achieve a clinical
response (such as ACR outcomes or disease remission, table 3).
Second, whereas achievement of clinical response (as measured
by the three secondary outcomes) was generally associated with
greater likelihood of continuing to work among DMARD
patients, this was not the case for adalimumab patients
Table 2 Analysis of the impact of adalimumab compared with disease-
modifying antirheumatic drug (DMARD) treatment on work outcomes
Adalimumab vs DMARD-treated
patients (95% CI)
Additional duration worked (years)*
All patients 0.17 (0.11 to 0.22)
Patients working at baseline 0.61 (0.42 to 0.79)
Hazard ratio for stopping work{
All patients 0.36 (0.30 to 0.42)
Patients working at baseline 0.36 (0.15 to 0.85)
*Duration worked for patients receiving adalimumab versus DMARDs from
multivariate ordinary least-square regression controlling for percentage working at
baseline (for analysis of all patients only) and baseline age, erythrocyte sedimentation
rate, C-reactive protein concentration, number of swollen and tender joints, 28-joint
Disease Activity Score, and joint pain, patient-rated global and physician-rated global
assessment visual analogue scale scores.
{Hazard ratio for patients receiving adalimumab compared with DMARDs from
proportional hazards regression controlling for time to event (stopping work), duration
of study enrolment, percentage working at baseline (for analysis of all patients only),
and baseline age, erythrocyte sedimentation rate, C-reactive protein, number of
swollen and tender joints, 28-joint Disease Activity Score, and joint pain, patient-rated
global and physician-rated global assessment visual analogue scale scores.
Table 3 Proportional hazards analysis of the impact of adalimumab
versus disease-modifying antirheumatic drug therapy on American
College of Rheumatology (ACR) response, European League Against
Rheumatism (EULAR) good response and 28-joint Disease Activity Score
(DAS28) remission*
Outcome
Hazard ratio among DE033
patients (95% CI)
Achieve ACR20 1.890 (1.477 to 2.419)
Achieve ACR50 1.949 (1.353 to 2.806)
Achieve ACR70 2.088 (1.137 to 3.836)
Achieve EULAR good response 1.625 (1.188 to 2.224)
Achieve disease remission—all patients 1.826 (1.323 to 2.520)
Achieve disease remission—patients without remission
at study enrolment
2.511 (1.721 to 3.662)
*From proportional hazards regressions controlling for time to event (ACR response or
disease remission), duration of study enrolment, percentage working at baseline (for
analysis of all patients only) and baseline age, erythrocyte sedimentation rate, C-
reactive protein concentration, number of swollen and tender joints, DAS28, and joint
pain, patient-rated global and physician-rated global assessment visual analogue scale
scores.
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independent of achieving clinical responses among the patients
receiving adalimumab.
The second finding is particularly exciting. It suggests that
although the effect of DMARDs on continued working is
related to improved clinical responses, the greater effect of
adalimumab on continuing work involves processes indepen-
dent of improved clinical responses (which were also signifi-
cantly associated with adalimumab treatment). Although the
mechanism of action of adalimumab and other anti-TNF agents
is not completely understood, it is clear that the biological
effects of these agents are different from those of DMARDs. For
example, anti-TNF agents have been shown to stimulate
production of new autoantibodies (eg, antinuclear antibodies)
but reduce production of serum rheumatoid factor and antic-
yclic citrullinated peptide antibodies.
42 In addition, adalimumab
and certain other anti-TNF agents have been shown to produce
complement-dependent lysis and antibody-dependent cellular
cytotoxicity and to reduce the numbers of infiltrating synovial
granulocyte.
43 Clinical studies also support differences in the
process by which adalimumab and DMARDs can lead to
increased duration of working. Anti-TNF agents can produce
substantial slowing of radiographic damage compared with
DMARD therapy,
44 and adalimumab has been shown to
markedly slow radiographic progression.
45 Slowed radiographic
progression has been correlated with clinical and work findings,
in that a recently published longitudinal study showed that
radiographic changes and disease activity independently
affected physical function among RA patients.
46 Increased
radiographic joint damage and lower Health Assessment
Questionnaire (HAQ) scores were also independently associated
with work status.
23 Further, studies in individuals treated with
adalimumab have indicated that, although baseline total Sharpe
score (TSS) was associated with change in employment status,
baseline DAS28 was not.
47 The present study expands this
previous work, and suggests further differentiation in the effects
of adalimumab and DMARDs in the treatment of RA.
This study also presents a notable method for evaluating the
impact of a treatment when no control group is present.
Although the gold standard for clinical trials involves randomis-
ing patients to experimental and control groups, such rando-
misation is not always feasible. In the case of DE033, patients
were already receiving adalimumab and could not be rando-
mised to another treatment group. In scenarios where rando-
misation is not possible or practical, use of separate control
groups is a well-established technique. Separate control groups
have been used for clinical studies in a diverse range of
therapeutic areas.
48–51 A separate control group was used in a
study of RA that evaluated the impact of etanercept on
employment.
30 Randomised controlled trials of RA medications
may overestimate patient outcomes.
52 Thus, our use of two
naturalistic, non-randomised studies to evaluate treatment
Table 4 Impact of American College of Rheumatology (ACR) and disease remission status on stopping
work*
Hazard ratio (95% CI)
For stopping work
based on achieving
ACR outcomes
For adalimumab
patients For DMARD patients
ACR outcome achieved at 6 months
ACR20
(n=67 adalimumab, n=130 comparison)
0.555 (0.457 to 0.674) 1.011 (0.722 to 1.417) 0.476 (0.375 to 0.604)
ACR50
(n=44 adalimumab, n=28 comparison)
0.685 (0.506 to 0.929) 0.894 (0.523 to 1.526) 0.619 (0.428 to 0.896)
ACR70
(n=5 adalimumab, n=12 comparison)
0.628 (0.344 to 1.147) 0.447 (0.061 to 3.253) 0.647 (0.343 to 1.220)
ACR outcome achieved at 12 months
ACR20
(n=91 adalimumab, n=91 comparison)
0.603 (0.493 to 0.737) 0.993 (0.727 to 1.356) 0.481 (0.367 to 0.630)
ACR50
(n=36 adalimumab, n=37 comparison)
0.639 (0.474 to 0.862) 0.985 (0.619 to 1.568) 0.539 (0.364 to 0.798)
ACR70
(n=9 adalimumab, n=12 comparison)
0.521 (0.291 to 0.931) 0.793 (0.195 to 3.226) 0.530 (0.279 to 1.004)
ACR outcome achieved at 24 months
ACR20
(n=105 adalimumab, n=62 comparison)
0.514 (0.418 to 0.633) 1.011 (0.753 to 1.359) 0.345 (0.251 to 0.475)
ACR50
(n=50 adalimumab, n=25 comparison)
0.572 (0.422 to 0.776) 1.050 (0.695 to 1.588) 0.395 (0.247 to 0.632)
ACR70
(n=20 adalimumab, n=10 comparison)
0.588 (0.367 to 0.943) 1.052 (0.579 to 1.912) 0.351 (0.155 to 0.795)
Impacts based on DAS28 scores
EULAR response
(n=97 adalimumab, n=118 comparison)
0.572 (0.475 to 0.688) 1.001 (0.753 to 1.331) 0.452 (0.354 to 0.578)
Disease remission
(n=165 adalimumab, n=85 comparison)
0.669 (0.551 to 0.812) 1.007 (0.753 to 1.345) 0.524 (0.391 to 0.702)
*From proportional hazards regressions controlling for time to event (stopping work), duration of study enrolment, treatment type
(adalimumab vs disease-modifying antirheumatic drugs), percentage working at baseline, and baseline age, erythrocyte
sedimentation rate, C-reactive protein, number of swollen and tender joints, 28-joint Disease Activity Score, and joint pain, patient-
rated global and physician-rated global assessment visual analogue scale scores.
EULAR, European League Against Rheumatism.
Extended report
934 Ann Rheum Dis 2009;68:930–937. doi:10.1136/ard.2008.092734differences may provide results that are more generalisable to
typical clinical practice.
The present study has a number of similarities to that of
Yelin et al,
30 which focused on employment outcomes among
patients with RA who had received etanercept in a clinical trial.
Outcomes for these patients were compared with outcomes for
patients in an observational study not receiving etanercept.
Multivariate regression analysis was used to control for baseline
patient characteristics in evaluating differences in rate of
employment between the two populations. Yelin et al had
more detailed information on hours worked per week and were
able to project differences in average hours per week, but the
study involved a smaller population of patients (total of 497 in
both groups), and all patients were enrolled at one institution.
The present study results are similar to those of Yelin et al and
help generalise these methods by including a larger study
population, as well as patients recruited from multiple interna-
tional treatment centres.
A number of other studies have performed related analyses.
van der Heijde et al
53 reported decreased work limitations and
increased productivity among patients with ankylosing spon-
dylitis treated with infliximab. However, Smolen et al
54 reported
no difference in employment rates between patients with RA
treated with infliximab plus methotrexate versus those treated
with methotrexate alone. Puolakka et al
55 found decreased rates
of work disability among patients with RA treated with
combination DMARD therapy versus those receiving a single
DMARD. Puolakka et al
56 also found that global assessments of
RA severity and HAQ scores were important predictors of
productivity loss and work disability among patients with RA.
Kavanaugh et al
23 also found an important association between
functional status or radiographic joint damage and employment
status.
Beyond the use of a separate control group, this study has
other limitations. There were significant differences between
the adalimumab and DMARD populations in a number of
baseline characteristics, which were addressed by performing
multivariate regression analyses. However, there are probably
other differences between the populations that were not
observed and thus could not be controlled for using this
technique, such as differences in eligibility for work disability
and pensions in different country. One study found that work
disability among early RA patients was 2.6-fold greater in
Finland than in the USA.
57 However, a recent report
29 indicated
that the achievement of work disability in RA was similar
between multiple countries. Thus, because our population was
more similar to the latter study than an early RA population,
we believe this difference is unlikely to substantially affect the
findings of the present study. The patients in the NOR-
DMARD group were new to methotrexate or leflunomide after
failing to respond to at least one DMARD treatment, whereas a
percentage of patients in the DE033 study previously might
have experienced a positive response with adalimumab.
In addition, duration of follow-up during the 2-year study
period was variable among the DMARD patients. This variation
may affect outcomes over time, as patients with greater illness
or functional limitations might be more likely to discontinue
participation in the DMARD registry. However, discontinua-
tion by these patients would leave a DMARD comparison group
with less illness or greater functional ability, thus potentially
biasing results against the adalimumab population. Further, by
using PH analysis, we controlled for the duration of study
enrolment on both work and secondary clinical response
outcomes.
Another important difference between the groups was the
manner in which they enrolled in the respective studies. The
DMARD patients enrolled in a registry and included individuals
with a range of disease durations, prior treatments and disease
severity. In contrast, the adalimumab patients had all been
participants in adalimumab clinical trials; these patients had not
responded to previous RA treatment, and had at least a
minimum level of clinical symptoms and functional impair-
ment. By restricting the DMARD patients to those in whom
treatment with at least one previous DMARD had failed, we
hoped to identify a population similar to the adalimumab
patients. However, at baseline, the DMARD patients had (on
average) more functional impairment and greater severity of
clinical symptoms that did the adalimumab patients. This may
reflect that the adalimumab patients were part of an open-label
extension study involving this medication. As such, they had all
received adalimumab (standard or low dose) or placebo in
double-blind, placebo controlled studies and may have received
clinical benefit from these treatments. Even patients with RA
receiving placebo in clinical trials may experience clinical
improvement.
58 Thus, patients who began the open-label study
may have been successfully treated with adalimumab and those
who had an unsatisfactory experience may have dropped out
prior to the open-label extension, whereas the DMARD-treated
patients may not have been successfully treated at enrolment.
The evaluation of changes over time may thus bias the present
study against the adalimumab patients. As they had already
been successfully treated, there was less likelihood of showing
subsequent improvement over time, such as changes in ACR or
EULAR response criteria. Nonetheless, the patients receiving
adalimumab showed significant improvements in outcomes
compared with those receiving DMARDs (table 3).
We chose to compare patients in the NOR-DMARD registry
with the DE033 study because data collection was similar
between these studies. In both studies, patients used self-report
questionnaires. In the DE033 study, patients were asked about
their working status: whether they were employed, the number
of days per week worked, the hours worked per day; whether
they were self-employed, homemakers, pensioner/retirees,
unemployed, students, or other; and whether they missed work
because of their RA within the past 6 months and how many
days of work had been missed. NOR-DMARD patients were
asked about their occupation, whether they worked full time or
part time, were on sick leave, crippled, or retired. No
information was collected on each patient’s job or position.
Many patients may have changed to an easier job to maintain
with this disease; therefore, physically demanding jobs may be
under-represented. Our study also did not differentiate between
part-time and full-time work, which may have affected the
results.
Despite these limitations, this study presents important
findings for treatment of patients with RA. Patients receiving
adalimumab were able to continue working longer and showed
greater clinical/functional status improvement than did those
receiving DMARDs. The ability to continue working translates
directly into economic outcomes. The average monthly wages
in Norway (for all salaried employees) was NOK29200 in
2005.
59 This corresponds to approximately J3589.
60 Thus, the
additional time worked among adalimumab patients corresponds
to more than J7179 in earnings per patient over the 2-year study
period. For those patients who were working at baseline, the
difference in time worked (0.61 years) corresponds to increased
earnings of more than J26000 for adalimumab patients. Thus,
adalimumab treatment may not only improve clinical status but
Extended report
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treatment and reduce the social support to compensate for these
lost earnings. On both individual and societal levels, the ability to
continue working is a factor of major economic and quality-of-life
importance for patients with RA.
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